Skip to main content
Top
Published in: BMC Nephrology 1/2020

Open Access 01-12-2020 | Chronic Kidney Disease | Research article

Vascular calcification in skin and subcutaneous tissue in patients with chronic and end-stage kidney disease

Authors: Irene Ruderman, Tim D. Hewitson, Edward R. Smith, Stephen G. Holt, Belinda Wigg, Nigel D. Toussaint

Published in: BMC Nephrology | Issue 1/2020

Login to get access

Abstract

Background

Vascular calcification (VC) is well described in large- and medium-sized vessels in patients with chronic kidney disease (CKD), especially in those with end-stage kidney disease (ESKD) on dialysis. Medial calcification is particularly prevalent in this population and contributes to arterial stiffness and increased cardiovascular mortality and morbidity. Apart from in the setting of calciphylaxis, few studies have assessed skin and subcutaneous calcification and associations with abnormalities of bone and mineral metabolism in patients with CKD.

Methods

We performed a single-centre observational study to evaluate incisional skin tissue samples from three anatomical sites in patients with different stages of CKD undergoing elective surgery. We compared these samples to skin samples of a control cohort without CKD. Staining for calcification was performed with von Kossa method. A subgroup of skin samples were assessed by RT-PCR for upregulation of pro-calcific gene transcripts for tissue non-specific alkaline phosphatase (TNAP) and Runt-related transcription factor 2 (RUNX2).

Results

Forty-five patients were evaluated, 34 with CKD (including ESKD) and 11 control patients. VC was identified in 15 skin samples (13 CKD/ESKD and 2 controls). VC was present in the dermal and subcutaneous tissues of the neck, abdomen and arm samples. Two different histological types of VC were identified: speckled medial calcification and internal elastic lamina calcification. Presence of perieccrine calcification was identified in 14 samples, 10 with concurrent VC. There were no significant differences in serum parathyroid hormone, phosphate or calcium in patients with or without VC. Expression of TNAP or RUNX2 was not increased in samples from patients with ESKD or those with histological evidence of calcification.

Conclusion

This study reports the novel finding of dermal and subcutaneous calcification in multiple anatomical locations in 38% of patients with advanced CKD/ESKD undergoing elective surgery but free from calciphylaxis.
Literature
1.
go back to reference Ruderman I, Holt SG, Hewitson TD, et al. Current and potential therapeutic strategies for the management of vascular calcification in patients with chronic kidney disease including those on dialysis. Semin Dial. 2018;31(5):487–99.CrossRef Ruderman I, Holt SG, Hewitson TD, et al. Current and potential therapeutic strategies for the management of vascular calcification in patients with chronic kidney disease including those on dialysis. Semin Dial. 2018;31(5):487–99.CrossRef
2.
go back to reference Smith ER, Hewitson TD, Holt SG. Diagnostic tests for vascular calcification. Adv Chronic Kidney Dis. 2019;26(6):445–63.CrossRef Smith ER, Hewitson TD, Holt SG. Diagnostic tests for vascular calcification. Adv Chronic Kidney Dis. 2019;26(6):445–63.CrossRef
3.
go back to reference Goodman WG, Goldin J, Kuizon BD, et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med. 2000;342(20):1478–83.CrossRef Goodman WG, Goldin J, Kuizon BD, et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med. 2000;342(20):1478–83.CrossRef
4.
go back to reference London GM, Guerin AP, Marchais SJ, et al. Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant. 2003;18:1731–40.CrossRef London GM, Guerin AP, Marchais SJ, et al. Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant. 2003;18:1731–40.CrossRef
5.
go back to reference Blacher J, Guerin AP, Pannier B, et al. Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension. 2001;38(4):938–42.CrossRef Blacher J, Guerin AP, Pannier B, et al. Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension. 2001;38(4):938–42.CrossRef
6.
go back to reference O'Neill WC, Adams AL. Breast arterial calcification in chronic kidney disease: absence of smooth muscle apoptosis and osteogenic transdifferentiation. Kidney Int. 2014;85(3):668–76.CrossRef O'Neill WC, Adams AL. Breast arterial calcification in chronic kidney disease: absence of smooth muscle apoptosis and osteogenic transdifferentiation. Kidney Int. 2014;85(3):668–76.CrossRef
7.
go back to reference Ellis CL, O'Neill WC. Questionable specificity of histologic findings in calcific uremic arteriolopathy. Kidney Int. 2018;94(2):390–5.CrossRef Ellis CL, O'Neill WC. Questionable specificity of histologic findings in calcific uremic arteriolopathy. Kidney Int. 2018;94(2):390–5.CrossRef
8.
go back to reference Mochel MC, Arakaki RY, Wang G, et al. Cutaneous calciphylaxis: a retrospective histopathologic evaluation. Am J Dermatopathol. 2013;35(5):582–6.CrossRef Mochel MC, Arakaki RY, Wang G, et al. Cutaneous calciphylaxis: a retrospective histopathologic evaluation. Am J Dermatopathol. 2013;35(5):582–6.CrossRef
9.
go back to reference Essary LR, Wick MR. Cutaneous calciphylaxis. An underrecognized clinicopathologic entity. Am J Clin Pathol. 2000;113(2):280–7.CrossRef Essary LR, Wick MR. Cutaneous calciphylaxis. An underrecognized clinicopathologic entity. Am J Clin Pathol. 2000;113(2):280–7.CrossRef
10.
go back to reference Weenig RH, Sewell LD, Davis MD, et al. Calciphylaxis: natural history, risk factor analysis, and outcome. J Am Acad Dermatol. 2007;56(4):569–79.CrossRef Weenig RH, Sewell LD, Davis MD, et al. Calciphylaxis: natural history, risk factor analysis, and outcome. J Am Acad Dermatol. 2007;56(4):569–79.CrossRef
11.
go back to reference Brandenburg VM, Sinha S, Specht P, et al. Calcific uraemic arteriolopathy: a rare disease with a potentially high impact on chronic kidney disease-mineral and bone disorder. Pediatr Nephrol. 2014;29(12):2289–98.CrossRef Brandenburg VM, Sinha S, Specht P, et al. Calcific uraemic arteriolopathy: a rare disease with a potentially high impact on chronic kidney disease-mineral and bone disorder. Pediatr Nephrol. 2014;29(12):2289–98.CrossRef
12.
go back to reference Nigwekar SU. Calciphylaxis. Curr Opin Nephrol Hypertens. 2017;26(4):276–81.CrossRef Nigwekar SU. Calciphylaxis. Curr Opin Nephrol Hypertens. 2017;26(4):276–81.CrossRef
13.
go back to reference Cerio R, Calonje E. Histopathology of the skin: general principles. Oxford: Wiley-Blackwell; 2010. Cerio R, Calonje E. Histopathology of the skin: general principles. Oxford: Wiley-Blackwell; 2010.
14.
go back to reference Vinay Kumar RSCSLR, with illustrations by James AP. Robbins basic pathology. Seventh edition. Philadelphia, PA : Saunders, [2003] ©2003, Placed Published: 2003. Vinay Kumar RSCSLR, with illustrations by James AP. Robbins basic pathology. Seventh edition. Philadelphia, PA : Saunders, [2003] ©2003, Placed Published: 2003.
15.
go back to reference Kramann R, Brandenburg VM, Schurgers LJ, et al. Novel insights into osteogenesis and matrix remodelling associated with calcific uraemic arteriolopathy. Nephrol Dial Transplant. 2013;28(4):856–68.CrossRef Kramann R, Brandenburg VM, Schurgers LJ, et al. Novel insights into osteogenesis and matrix remodelling associated with calcific uraemic arteriolopathy. Nephrol Dial Transplant. 2013;28(4):856–68.CrossRef
16.
go back to reference Pai A, Leaf EM, El-Abbadi M, et al. Elastin degradation and vascular smooth muscle cell phenotype change precede cell loss and arterial medial calcification in a uremic mouse model of chronic kidney disease. Am J Pathol. 2011;178(2):764–73.CrossRef Pai A, Leaf EM, El-Abbadi M, et al. Elastin degradation and vascular smooth muscle cell phenotype change precede cell loss and arterial medial calcification in a uremic mouse model of chronic kidney disease. Am J Pathol. 2011;178(2):764–73.CrossRef
17.
go back to reference Shanahan CM, Cary NR, Salisbury JR, et al. Medial localization of mineralization-regulating proteins in association with Monckeberg’s sclerosis: evidence for smooth muscle cell-mediated vascular calcification. Circulation. 1999;100(21):2168–76.CrossRef Shanahan CM, Cary NR, Salisbury JR, et al. Medial localization of mineralization-regulating proteins in association with Monckeberg’s sclerosis: evidence for smooth muscle cell-mediated vascular calcification. Circulation. 1999;100(21):2168–76.CrossRef
18.
go back to reference Dookhan C, Ortega LM, Nayer A, et al. Perieccrine and pericapillary calcification in calciphylaxis. J Ren Inj Prev. 2015;4(1):9–10.PubMed Dookhan C, Ortega LM, Nayer A, et al. Perieccrine and pericapillary calcification in calciphylaxis. J Ren Inj Prev. 2015;4(1):9–10.PubMed
19.
go back to reference Gross ML, Meyer HP, Ziebart H, et al. Calcification of coronary intima and media: immunohistochemistry, backscatter imaging, and x-ray analysis in renal and nonrenal patients. Clin J Am Soc Nephrol. 2007;2(1):121–34.CrossRef Gross ML, Meyer HP, Ziebart H, et al. Calcification of coronary intima and media: immunohistochemistry, backscatter imaging, and x-ray analysis in renal and nonrenal patients. Clin J Am Soc Nephrol. 2007;2(1):121–34.CrossRef
20.
go back to reference Schlieper G, Aretz A, Verberckmoes SC, et al. Ultrastructural analysis of vascular calcifications in uremia. J Am Soc Nephrol. 2010;21(4):689–96.CrossRef Schlieper G, Aretz A, Verberckmoes SC, et al. Ultrastructural analysis of vascular calcifications in uremia. J Am Soc Nephrol. 2010;21(4):689–96.CrossRef
21.
go back to reference Lin ME, Chen T, Leaf EM, et al. Runx2 expression in smooth muscle cells is required for arterial medial calcification in mice. Am J Pathol. 2015;185(7):1958–69.CrossRef Lin ME, Chen T, Leaf EM, et al. Runx2 expression in smooth muscle cells is required for arterial medial calcification in mice. Am J Pathol. 2015;185(7):1958–69.CrossRef
22.
go back to reference Donate-Correa J, Martín-Núñez E, Hernández-Carballo C, et al. Fibroblast growth factor 23 expression in human calcified vascular tissues. Aging. 2019;11(18):7899–913.CrossRef Donate-Correa J, Martín-Núñez E, Hernández-Carballo C, et al. Fibroblast growth factor 23 expression in human calcified vascular tissues. Aging. 2019;11(18):7899–913.CrossRef
23.
go back to reference Smith ER. Vascular calcification in uremia: new-age concepts about an old-age problem. Methods Mol Biol. 2016;1397:175–208.CrossRef Smith ER. Vascular calcification in uremia: new-age concepts about an old-age problem. Methods Mol Biol. 2016;1397:175–208.CrossRef
24.
go back to reference Hortells L, Sosa C, Guillen N, et al. Identifying early pathogenic events during vascular calcification in uremic rats. Kidney Int. 2017;92(6):1384–94.CrossRef Hortells L, Sosa C, Guillen N, et al. Identifying early pathogenic events during vascular calcification in uremic rats. Kidney Int. 2017;92(6):1384–94.CrossRef
Metadata
Title
Vascular calcification in skin and subcutaneous tissue in patients with chronic and end-stage kidney disease
Authors
Irene Ruderman
Tim D. Hewitson
Edward R. Smith
Stephen G. Holt
Belinda Wigg
Nigel D. Toussaint
Publication date
01-12-2020
Publisher
BioMed Central
Published in
BMC Nephrology / Issue 1/2020
Electronic ISSN: 1471-2369
DOI
https://doi.org/10.1186/s12882-020-01928-0

Other articles of this Issue 1/2020

BMC Nephrology 1/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.